The FASEB Journal: New psoriatric arthritis mouse model developed

June 06, 2019

Psoriatic arthritis (PsA) is a chronic inflammatory disease that can reduce mobility and agility in patients. PsA is known to increase the risk of type II diabetes. A recent study published in The FASEB Journal tested a novel mouse model that may one day lead to therapeutic approaches or reagents for human skin pathology, as well as joint erosion and disc degeneration, that would improve quality of life for patients with PsA.

To conduct the study, researchers used two groups of non-obese diabetic (NOD) mice. One group was infected with an adenoviral vector engineered to express a single-chain IL-23 (pro-inflammatory cytokine), while the other was infected with a control virus. The group infected with the IL-23 virus developed PsA following a single intravenous injection. The systemic delivery of the virus allowed for the development of a broad array of symptoms often seen in human PsA patients, including skin, disc, and joint disease. The development of these symptoms makes this the only mouse model of PsA.

"This novel mouse model represents an excellent model of human PsA that encompasses most symptoms of human disease," said Paul Robbins, professor of biochemistry, molecular biology, and biophysics at the University of Minnesota. "The model can be used to test and optimize PsA therapies, thus improving quality of life for PsA patients."

In another surprising finding, the research team observed that IL-23 did not accelerate diabetes, but actually delayed the onset of hyperglycemia, or high blood sugar.

"This disease has needed a robust animal model system for some time and this study constitutes such an advance," said Thoru Pederson, PhD, Editor-in-Chief of The FASEB Journal.
-end-
The FASEB Journal is published by the Federation of the American Societies for Experimental Biology (FASEB). The world's most cited biology journal according to the Institute for Scientific Information, it has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century.

FASEB is composed of 29 societies with more than 130,000 members, making it the largest coalition of biomedical research associations in the United States. FASEB's mission is to advance health and well-being by promoting research and education in biological and biomedical sciences through collaborative advocacy and service to member societies and their members.

Federation of American Societies for Experimental Biology

Related Psoriatic Arthritis Articles from Brightsurf:

Is rheumatoid arthritis two different diseases?
While disease activity improves over time for most rheumatoid arthritis (RA) patients, long-term outcomes only improve in RA patients with autoantibodies, according to a new study published this week in PLOS Medicine by Xanthe Matthijssen of Leiden University Medical Center, Netherlands, and colleagues.

Key discovery in psoriatic arthritis points way for developing targeted treatments
The strongest evidence yet of a single cause for psoriatic arthritis has been discovered by researchers.

Evaluating risk of cancer in patients with psoriasis, psoriatic arthritis
This observational study was a systematic review and meta-analysis that included 112 studies and examined the association between risk of cancer in patients with psoriasis or psoriatic arthritis, including the risk of specific cancers.

Psoriasis onset determines if psoriatic arthritis patients develop arthritis or psoriasis first
In a new study presented at the 2019 ACR/ARP Annual Meeting, researchers found the age of psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis.

Tildrakizumab shows promising efficacy and safety in psoriatic arthritis
The results of a phase 2B study presented today at the Annual European Congress of Rheumatology (EULAR 2019) demonstrate superior efficacy and comparable safety of tildrakizumab versus placebo in patients with psoriatic arthritis.

No link between cancer and tumor necrosis factor inhibitor (TNFi) use in psoriatic arthritis
The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019) suggest that overall cancer risk is not linked to tumor necrosis factor inhibitor (TNFi) use in psoriatic arthritis.

Being overweight linked to significantly higher disease severity in psoriatic arthritis
The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019) demonstrate significant correlation between body mass index (BMI) and disease severity in psoriatic arthritis.

Imaging tests help reveal heart risks in patients with psoriatic disease
Patients with psoriasis and psoriatic arthritis -- collectively termed psoriatic disease -- face increased heart risks.

The ACR and the Arthritis Foundation present new guidelines offering therapeutic approaches and treatment options for juvenile idiopathic arthritis
Today, the American College of Rheumatology (ACR), in partnership with the Arthritis Foundation (AF), released two guidelines on juvenile idiopathic arthritis (JIA).

Does alcohol consumption have an effect on arthritis?
Several previous studies have demonstrated that moderate alcohol consumption is linked with less severe disease and better quality of life in patients with rheumatoid arthritis, but a new Arthritis Care & Research study suggests that this might not be because drinking alcohol is beneficial.

Read More: Psoriatic Arthritis News and Psoriatic Arthritis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.